Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effects of Canola Oil on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis With Dose-Response Analysis of Controlled Clinical Trials Publisher Pubmed



Amiri M1, 2, 3 ; Raeisidehkordi H1, 2, 3 ; Sarrafzadegan N4, 5 ; Forbes SC6 ; Salehiabargouei A2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  2. 2. Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  3. 3. Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  4. 4. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, Canada
  6. 6. Department of Physical Education, Faculty of Education, Brandon University, Brandon, MB, Canada

Source: Nutrition, Metabolism and Cardiovascular Diseases Published:2020


Abstract

Background and aims: Canola oil (CO) is a plant-based oil with the potential to improve several cardiometabolic risk factors. We systematically reviewed controlled clinical trials investigating the effects of CO on lipid profiles, apo-lipoproteins, glycemic indices, inflammation, and blood pressure compared to other edible oils in adults. Methods and results: Online databases were searched for articles up to January 2020. Forty-two articles met the inclusion criteria. CO significantly reduced total cholesterol (TC, −0.27 mmol/l, n = 37), low-density lipoprotein cholesterol (LDL-C, −0.23 mmol/l, n = 35), LDL-C to high-density lipoprotein cholesterol ratio (LDL/HDL, −0.21, n = 10), TC/HDL (−0.13, n = 15), apolipoprotein B (Apo B, −0.03 g/l, n = 14), and Apo B/Apo A-1 (−0.02, n = 6) compared to other edible oils (P < 0.05). Compared to olive oil, CO decreased TC (−0.23 mmol/l, n = 9), LDL-C (−0.17 mmol/l, n = 9), LDL/HDL (−0.39, n = 2), and triglycerides in VLDL (VLDL-TG, −0.10 mmol/l, n = 2) (P < 0.05). Compared to sunflower oil, CO improved LDL-C (−0.14 mmol/l, n = 11), and LDL/HDL (−0.30, n = 3) (P < 0.05). In comparison with saturated fats, CO improved TC (−0.59 mmol/l, n = 11), TG (−0.08 mmol/l, n = 11), LDL-C (−0.49 mmol/l, n = 10), TC/HDL (−0.29, n = 5), and Apo B (−0.09 g/l, n = 4) (P < 0.05). Based on the nonlinear dose–response curve, replacing CO with ~15% of total caloric intake provided the greatest benefits. Conclusion: CO significantly improved different cardiometabolic risk factors compared to other edible oils. Further well-designed clinical trials are warranted to confirm the dose–response associations. © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University
Other Related Docs
48. Fatty Acid Composition of Commercially Available Iranian Edible Oils, Journal of Research in Medical Sciences (2009)